A Phase 2 interventional study of Guselkumab Dose 1 and Guselkumab Dose 2 in Scleroderma, Systemic, sponsored by Janssen Pharmaceutical K.K.. Completed at 4 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Scleroderma, Systemic by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Scleroderma, Systemic · Johnson & Johnson.
Among the 10 studies in Scleroderma, Systemic by Johnson & Johnson, this one is the only one that started in 2021, is one of 2 in phase 2, and was the 10th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →None of the 10 studies in Scleroderma, Systemic by Johnson & Johnson is open now. The open studies under Scleroderma, Systemic, anywhere →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 5 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 124 across the 8 interventional studies, 560 across the 2 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Scleroderma, Systemic by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intravenous (IV) injection of Guselkumab Dose 1 at Week 0, 4, and 8 followed by subcutaneous (SC) injection of Dose 2 Guselkumab every 4 weeks (Q4W) from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Guselkumab Dose 2 and IV injection of placebo at long-term extension (LTE) Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2
Participants will receive IV injection of matching placebo at Week 0, 4, and 8 followed by SC injection of matching placebo Q4W from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Placebo and IV injection of Guselkumab Dose 1 at LTE Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
Drug: Placebo
Guselkumab Dose 1 will be administered intravenously.
Guselkumab Dose 2 will be administered subcutaneously.
Placebo will be administered intravenously or subcutaneously.
Main Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24
Change from baseline in mRSS at Week 24 was reported. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.
Time frame: Baseline and Week 24
Main Study: Change From Baseline in Modified Rodnan Skin Score at Week 52
Change from baseline in mRSS at Week 52 was reported. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.
Time frame: Baseline and Week 52
Main Study: Percentage of Participants Who Experienced Worsening of Modified Rodnan Skin Score at Week 24 and Week 52
The percentage of participants who experienced worsening of mRSS at Week 24 and Week 52 was reported. The worsening of mRSS was defined as an increase from baseline greater than or equal to (\>=) 5 points and \>=20 percent (%) in mRSS. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.
Time frame: Week 24 and Week 52
Main Study: Percentage of Participants Who Achieved a Score of 0.6 in American College of Rheumatology Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (ACR CRISS) at Week 24 and Week 52
ACR CRISS is a composite endpoint. Firstly, participants were evaluated on not-improved criterion: new onset of renal crisis, \>=15% decline in forced vital capacity \[FVC\] percent predicted relative to baseline, new onset of pulmonary arterial hypertension, and new onset of left ventricular failure. If yes, these participants were assigned probability score of 0.0. For remaining participants, percentage was based on CRISS domains: mRSS, FVC percent predicted, physician's global assessment, patient's global assessment and Health Assessment Questionnaire Disability-Index (HAQ-DI). Algorithm determines predicted probability of improvement from baseline by incorporating change in mRSS, FVC percent predicted, physician and patient global assessments and HAQ-DI. Outcome was a continuous variable between 0.0 and 1.0 (0 to 100%). Higher score=greater probability of improvement. ACR CRISS score \>=0.60 was considered improved, while predicted probability below 0.60 was considered not improved.
Time frame: Week 24 and Week 52
Main Study: Change From Baseline in Forced Vital Capacity (FVC) at Week 24 and Week 52
FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.
Time frame: Baseline, Week 24 and Week 52
Main Study: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 24 and Week 52
Change from baseline in the percent predicted FVC at Week 24 and Week 52 was reported. FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.
Time frame: Baseline, Week 24 and Week 52
Main Study: Change From Baseline in the Measured Absolute Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) at Week 24 and Week 52
DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. DLCO is measured using the single breath method. Participants breathe in (inhale) air containing a very small, harmless amount of a tracer gas, such as carbon monoxide. Participants hold their breath for 10 seconds, then rapidly blow it out (exhale). The exhaled gas was tested to determine amount of the tracer gas absorbed during the breath.
Time frame: Baseline, Week 24 and Week 52
Main Study: Change From Baseline in the Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) at Week 24 and Week 52
Change from baseline in the percent predicted DLCO at Week 24 and Week 52 was reported. DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. DLCO is measured using the single breath method. Participants breathe in (inhale) air containing a very small, harmless amount of a tracer gas, such as carbon monoxide. Participants hold their breath for 10 seconds, then rapidly blow it out (exhale). The exhaled gas was tested to determine amount of the tracer gas absorbed during the breath.
Time frame: Baseline, Week 24 and Week 52
Main Study: Change From Baseline in Digital Ulcer Counts at Week 24 and Week 52
Digital ulcers were defined as a full thickness (\>3 millimeters \[mm\] in maximal diameter) skin lesion with loss of epithelium including lesions covered by eschar (excluding pitting scars and hyperkeratotic lesions). Healing was defined by re-epithelialization with loss of pain and exudate. The digital ulcer assessments and counting were performed by the investigator designee.
Time frame: Baseline, Week 24 and Week 52
Main Study: Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 and Week 52
HAQ-DI assessed the degree of difficulty participants experienced in 8 daily living activity domains during past week: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each activity category consisted of 2-3 items. For each item, level of difficulty was scored from 0 to 3 (0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do). Total HAQ-DI score was computed as the sum of domain scores divided by the number of domains answered, providing a score from 0 (no difficulty) to 3 (maximum difficulty), where higher score indicated greater disability.
Time frame: Baseline, Week 24 and Week 52
Main Study: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 24 and Week 52
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs that occur at or after the initial administration of study intervention. All TEAEs including serious and non-serious events are reported in this outcome measure.
Time frame: From Baseline (Week 0) up to Week 24 and Week 52
Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs that occurred at or after the initial administration of study intervention. All TEAEs including serious and non-serious events are reported in this outcome measure.
Time frame: From Week 52 up to Week 112
Main Study: Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 24 and Week 52
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TEAEs were defined as AEs that occur at or after the initial administration of study intervention.
Time frame: From Baseline (Week 0) up to Week 24 and Week 52
Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TEAEs were defined as AEs that occur at or after the initial administration of study intervention.
Time frame: From Week 52 up to Week 112
Main Study: Number of Participants With Adverse Events of Special Interest (AESI) Through Week 24 and Week 52
AESI were defined as any newly identified malignancy or case of active tuberculosis (TB) or interstitial lung disease (ILD) occurring after the first study intervention administration in study participants and was reported by the investigator to the sponsor or designee within 24 hours after being made aware of the event. AESIs for this study included drug-induced liver injuries, active TB, ILD, hypersensitivity reaction, opportunistic infection and adverse cardiovascular events.
Time frame: From Baseline (Week 0) up to Week 24 and Week 52
Long-term Extension (LTE) Period: Number of Participants With Adverse Events of Special Interest (AESI)
AESI were defined as any newly identified malignancy or case of active tuberculosis (TB) or interstitial lung disease (ILD) occurring after the first study intervention administration in study participants and was reported by the investigator to the sponsor or designee within 24 hours after being made aware of the event. AESIs for this study included drug-induced liver injuries, active TB, ILD, hypersensitivity reaction, opportunistic infection and adverse cardiovascular events.
Time frame: From Week 52 up to Week 112
Main Study: Serum Concentration of Guselkumab
Serum concentration of guselkumab was reported. The lower limit of quantification (LLOQ) for guselkumab was 0.01 micrograms per milliliter (mcg/mL).
Time frame: Pre-dose at Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and Post- dose at Weeks 0, 4, 8
Long-term Extension (LTE) Study: Serum Concentrations of Guselkumab
Serum concentration of guselkumab was reported. The LLOQ for guselkumab was 0.01 mcg/mL.
Time frame: Pre-dose (at Weeks 56, 60, 64, 76, 88, 96) and Week 104
Main Study: Number of Participants With Anti-Guselkumab Antibody
Number of participants with anti-guselkumab antibody were reported. Serum samples were assessed for anti-drug antibodies.
Time frame: From Baseline (Week 0) up to Week 52
Long-term Extension (LTE) Study: Number of Participants With Anti-guselkumab Antibody
Number of participants with anti-guselkumab antibody were reported. Serum samples were assessed for anti-drug antibodies.
Time frame: From Week 52 up to Week 104
Participants diagnosed with systemic sclerosis as per American College of Rheumatology and European League Against Rheumatism 2013 criteria with disease duration of less than or equal to (\<=) 36 months and Modified Rodnan Skin Score ranged from greater than or equal to (\>=) 10 to less than or equal to (\<=) 22 units were randomized into the study.
| Milestone | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|---|---|
| Started | 29 | 27 | 0 | 0 |
| Completed | 28 | 27 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|---|---|
| Started | 0 | 0 | 25 | 26 |
| Completed | 0 | 0 | 24 | 24 |
| Not completed | 0 | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
Change from baseline in mRSS at Week 24 was reported. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.
| Score on a scale | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Main Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 | -9.5 ± 0.74 | 3.1 ± 0.77 |
Change from baseline in mRSS at Week 52 was reported. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.
| Score on a scale | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Main Study: Change From Baseline in Modified Rodnan Skin Score at Week 52 | -9.3 ± 0.89 | 2.7 ± 0.93 |
The percentage of participants who experienced worsening of mRSS at Week 24 and Week 52 was reported. The worsening of mRSS was defined as an increase from baseline greater than or equal to (\>=) 5 points and \>=20 percent (%) in mRSS. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.
| Percentage of participants | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | 3.4 | 25.9 |
| Week 52 | 20.7 | 77.8 |
ACR CRISS is a composite endpoint. Firstly, participants were evaluated on not-improved criterion: new onset of renal crisis, \>=15% decline in forced vital capacity \[FVC\] percent predicted relative to baseline, new onset of pulmonary arterial hypertension, and new onset of left ventricular failure. If yes, these participants were assigned probability score of 0.0. For remaining participants, percentage was based on CRISS domains: mRSS, FVC percent predicted, physician's global assessment, patient's global assessment and Health Assessment Questionnaire Disability-Index (HAQ-DI). Algorithm determines predicted probability of improvement from baseline by incorporating change in mRSS, FVC percent predicted, physician and patient global assessments and HAQ-DI. Outcome was a continuous variable between 0.0 and 1.0 (0 to 100%). Higher score=greater probability of improvement. ACR CRISS score \>=0.60 was considered improved, while predicted probability below 0.60 was considered not improved.
| Percentage of participants | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | 86.2 | 3.7 |
| Week 52 | 79.3 | 3.7 |
FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.
| Liters | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | -51.9 ± 33.91 | -4.7 ± 35.78 |
| Week 52 | -26.5 ± 30.42 | -12.3 ± 32.15 |
Change from baseline in the percent predicted FVC at Week 24 and Week 52 was reported. FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.
| Percent predicted FVC | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | -0.7 ± 1.21 | -0.7 ± 1.26 |
| Week 52 | -0.2 ± 1.17 | -0.4 ± 1.22 |
DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. DLCO is measured using the single breath method. Participants breathe in (inhale) air containing a very small, harmless amount of a tracer gas, such as carbon monoxide. Participants hold their breath for 10 seconds, then rapidly blow it out (exhale). The exhaled gas was tested to determine amount of the tracer gas absorbed during the breath.
| Milliliter/minute/millimeter mercury | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | -0.60 ± 0.257 | -0.51 ± 0.265 |
| Week 52 | -0.35 ± 0.316 | -0.56 ± 0.327 |
Change from baseline in the percent predicted DLCO at Week 24 and Week 52 was reported. DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. DLCO is measured using the single breath method. Participants breathe in (inhale) air containing a very small, harmless amount of a tracer gas, such as carbon monoxide. Participants hold their breath for 10 seconds, then rapidly blow it out (exhale). The exhaled gas was tested to determine amount of the tracer gas absorbed during the breath.
| Percent predicted DLCO | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | -4.57 ± 1.338 | -2.49 ± 1.347 |
| Week 52 | -1.71 ± 1.541 | -1.85 ± 1.565 |
Digital ulcers were defined as a full thickness (\>3 millimeters \[mm\] in maximal diameter) skin lesion with loss of epithelium including lesions covered by eschar (excluding pitting scars and hyperkeratotic lesions). Healing was defined by re-epithelialization with loss of pain and exudate. The digital ulcer assessments and counting were performed by the investigator designee.
| Ulcers | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | -0.0 ± 0.47 | 4.8 ± 0.48 |
| Week 52 | -0.1 ± 0.55 | 4.1 ± 0.58 |
HAQ-DI assessed the degree of difficulty participants experienced in 8 daily living activity domains during past week: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each activity category consisted of 2-3 items. For each item, level of difficulty was scored from 0 to 3 (0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do). Total HAQ-DI score was computed as the sum of domain scores divided by the number of domains answered, providing a score from 0 (no difficulty) to 3 (maximum difficulty), where higher score indicated greater disability.
| Score on a scale | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | -0.0529 ± 0.09062 | 0.3477 ± 0.09439 |
| Week 52 | -0.0572 ± 0.08955 | 0.1782 ± 0.09321 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs that occur at or after the initial administration of study intervention. All TEAEs including serious and non-serious events are reported in this outcome measure.
| Participants | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | 20 | 24 |
| Week 52 | 25 | 26 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs that occurred at or after the initial administration of study intervention. All TEAEs including serious and non-serious events are reported in this outcome measure.
| Participants | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|
| Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 23 | 25 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TEAEs were defined as AEs that occur at or after the initial administration of study intervention.
| Participants | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | 0 | 0 |
| Week 52 | 1 | 1 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TEAEs were defined as AEs that occur at or after the initial administration of study intervention.
| Participants | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|
| Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | 1 | 0 |
AESI were defined as any newly identified malignancy or case of active tuberculosis (TB) or interstitial lung disease (ILD) occurring after the first study intervention administration in study participants and was reported by the investigator to the sponsor or designee within 24 hours after being made aware of the event. AESIs for this study included drug-induced liver injuries, active TB, ILD, hypersensitivity reaction, opportunistic infection and adverse cardiovascular events.
| Participants | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo |
|---|---|---|
| Week 24 | 0 | 0 |
| Week 52 | 1 | 2 |
AESI were defined as any newly identified malignancy or case of active tuberculosis (TB) or interstitial lung disease (ILD) occurring after the first study intervention administration in study participants and was reported by the investigator to the sponsor or designee within 24 hours after being made aware of the event. AESIs for this study included drug-induced liver injuries, active TB, ILD, hypersensitivity reaction, opportunistic infection and adverse cardiovascular events.
| Participants | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|
| Long-term Extension (LTE) Period: Number of Participants With Adverse Events of Special Interest (AESI) | 0 | 0 |
Serum concentration of guselkumab was reported. The lower limit of quantification (LLOQ) for guselkumab was 0.01 micrograms per milliliter (mcg/mL).
| mcg/mL | Main Study: Group A: Guselkumab |
|---|---|
| Pre-dose at Week 0 | NA ± NA |
| Post-dose at Week 0 | 140.880 ± 26.5879 |
| Pre-dose at Week 4 | 22.489 ± 6.9499 |
| Post-dose at Week 4 | 160.691 ± 31.7578 |
| Pre-dose at Week 8 | 27.968 ± 9.7988 |
| Post-dose at Week 8 | 164.633 ± 28.9999 |
| Pre-dose at Week 12 | 36.497 ± 13.7929 |
| Pre-dose at Week 16 | 21.697 ± 9.6355 |
| Pre-dose at Week 20 | 12.751 ± 6.0638 |
| Pre-dose at Week 24 | 13.981 ± 6.6055 |
| Pre-dose at Week 28 | 14.184 ± 5.6980 |
| Pre-dose at Week 32 | 12.564 ± 5.6367 |
| Pre-dose at Week 36 | 12.932 ± 6.4345 |
| Pre-dose at Week 40 | 13.375 ± 6.1989 |
| Pre-dose at Week 44 | 12.469 ± 6.8698 |
| Pre-dose at Week 48 | 12.074 ± 6.1027 |
| Pre-dose at Week 52 | 11.363 ± 6.6822 |
Serum concentration of guselkumab was reported. The LLOQ for guselkumab was 0.01 mcg/mL.
| mcg/mL | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|
| Pre-dose at Week 56 | 12.167 ± 5.4753 | 19.285 ± 8.3377 |
| Pre-dose at Week 60 | 12.704 ± 5.6942 | 25.925 ± 10.9856 |
| Pre-dose at Week 64 | 13.835 ± 7.3326 | 33.368 ± 14.8075 |
| Pre-dose at Week 76 | 11.641 ± 5.5746 | 13.200 ± 6.0810 |
| Pre-dose at Week 88 | 10.339 ± 5.1209 | 11.893 ± 6.3203 |
| Pre-dose at Week 96 | 10.082 ± 4.5371 | 12.426 ± 5.6925 |
| Week 104 | 10.080 ± 5.2596 | 12.301 ± 6.0099 |
Number of participants with anti-guselkumab antibody were reported. Serum samples were assessed for anti-drug antibodies.
| Participants | Main Study: Group A: Guselkumab |
|---|---|
| Main Study: Number of Participants With Anti-Guselkumab Antibody | 6 |
Number of participants with anti-guselkumab antibody were reported. Serum samples were assessed for anti-drug antibodies.
| Participants | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|
| Long-term Extension (LTE) Study: Number of Participants With Anti-guselkumab Antibody | 6 | 0 |
Collected over All-cause mortality: Main Study: From screening (Week [-6]) up to Week 60 and LTE Period: From Week 52 up to Week 112 ; SAEs and Non-serious AEs: Main Study: From baseline (Week 0) up to Week 60; LTE Period: From Week 52 up to Week 112. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study: Group A: Guselkumab | 0/29 (0%) | 1/29 (3.4%) | 22/29 (75.9%) |
| Main Study: Group B: Placebo | 0/27 (0%) | 1/27 (3.7%) | 26/27 (96.3%) |
| LTE Period: Group A: Guselkumab Then Guselkumab | 1/25 (4%) | 1/25 (4%) | 22/25 (88%) |
| LTE Period: Group B: Placebo Then Guselkumab | 0/26 (0%) | 0/26 (0%) | 22/26 (84.6%) |
| Event | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|---|---|
| MyocarditisCardiac disorders | 0/29 | 0/27 | 1/25 | 0/26 |
| Covid-19Infections and infestations | 0/29 | 1/27 | 0/25 | 0/26 |
| Ileus ParalyticGastrointestinal disorders | 1/29 | 0/27 | 0/25 | 0/26 |
| Pneumatosis IntestinalisGastrointestinal disorders | 1/29 | 0/27 | 0/25 | 0/26 |
| Systemic SclerodermaMusculoskeletal and connective tissue disorders | 1/29 | 0/27 | 0/25 | 0/26 |
| Event | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | LTE Period: Group A: Guselkumab Then Guselkumab | LTE Period: Group B: Placebo Then Guselkumab |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 9/29 | 14/27 | 4/25 | 7/26 |
| NasopharyngitisInfections and infestations | 6/29 | 2/27 | 12/25 | 9/26 |
| Covid-19Infections and infestations | 2/29 | 2/27 | 7/25 | 6/26 |
| Neutrophil Count DecreasedInvestigations | 0/29 | 7/27 | 0/25 | 0/26 |
| White Blood Cell Count DecreasedInvestigations | 0/29 | 7/27 | 0/25 | 0/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/29 | 7/27 | 1/25 | 1/26 |
| EczemaSkin and subcutaneous tissue disorders | 0/29 | 7/27 | 1/25 | 0/26 |
| ParonychiaInfections and infestations | 4/29 | 5/27 | 2/25 | 2/26 |
| Dermatitis ContactSkin and subcutaneous tissue disorders | 5/29 | 4/27 | 0/25 | 2/26 |
| InfluenzaInfections and infestations | 0/29 | 0/27 | 0/25 | 4/26 |
| Age, Continuous(Years) | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | Total |
|---|---|---|---|
| Mean | 51.3 ± 13.26 | 50.8 ± 12.18 | 51.1 ± 12.64 |
| Age, Customized(Participants) | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | Total |
|---|---|---|---|
| 18 to 64 years | 25 | 23 | 48 |
| 65 years and over | 4 | 4 | 8 |
| Sex: Female, Male(Participants) | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | Total |
|---|---|---|---|
| Female | 26 | 21 | 47 |
| Male | 3 | 6 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 28 | 27 | 55 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 28 | 27 | 55 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Main Study: Group A: Guselkumab | Main Study: Group B: Placebo | Total |
|---|---|---|---|
| JAPAN | 29 | 27 | 56 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Feb 2021 to primary completion in May 2023, 26 months.
Results were first posted in Oct 2024, 1 year 4 months after primary completion.
Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab